News Releases

Date Title  
02/14/19
Summary TogglePLx Pharma Inc. Announces Adjournment of Special Meeting of Stockholders
HOUSTON , Feb. 14, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“ PLx ” or the “ Company ”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “ Vazalore ”™), announced
PDF Version
12/20/18
Summary TogglePLx Pharma Inc. Announces $15 Million Convertible Preferred Stock Financing
HOUSTON , Dec. 20, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced today it
PDF Version
12/18/18
Summary TogglePLx Pharma Inc. to Present at Biotech Showcase 2019
HOUSTON , Dec. 18, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced today
PDF Version
11/09/18
Summary TogglePLx Pharma Inc. Reports Third Quarter 2018 Results
PLx has identified the alternate supply of a key ingredient for Vazalore HOUSTON , Nov. 09, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and
PDF Version
11/01/18
Summary TogglePLx Pharma Inc. to Discuss 2018 Third Quarter Financial Results on November 9, 2018 Conference Call
HOUSTON , Nov. 01, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced today
PDF Version
09/10/18
Summary TogglePLx Pharma Inc. to Present at Janney Healthcare Conference on September 18

HOUSTON , Sept. 10, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced today
PDF Version
08/10/18
Summary TogglePLx Pharma Inc. Reports Second Quarter 2018 Results

Announces that FDA has approved new name Vazalore for PLx’s next generation, novel aspirin HOUSTON , Aug. 10, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products,
PDF Version
06/11/18
Summary TogglePLx Pharma Inc. to Present at JMP Securities Life Sciences Conference

HOUSTON , June 11, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
05/11/18
Summary TogglePLx Pharma Inc. Reports First Quarter 2018 Results

HOUSTON , May 11, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
03/23/18
Summary TogglePLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results
HOUSTON , March 23, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
Displaying 1 - 10 of 28 results